A Supreme Court decision handed down last month and previously addressed on this blog may have huge implications not only for the pharmaceutical and medical device industry, but for product liability laws across most manufacturers’ product lines as well.
If you recall, the Supreme Court overwhelmingly ruled in favor of Bristol-Myers Squibb by 8-1 in June. At question was whether plaintiffs from states other than California could join ...
continue reading...
The U.S. Court of Appeals for the First Circuit has sided with a woman previously awarded $21.06 million in damages against the manufacturer Clinoril, which caused her permanent near blindness and skin burns over about 60 percent of her body in a condition known as Stevens-Johnson Syndrome, or SJS.
The May 2 decision regarding ...
continue reading...Many patients’ rights groups are criticizing a measure that passed in the U.S. House of Representatives last week, which would restrict patients’ ability to pursue claims against negligent medical providers, including drug and medical device manufacturers.
According to Public Citizen, H.R. 5, the Protecting Access to Healthcare (PATH) Act, imposes an arbitrary $250,000 cap on non-economic damages, which would have a disproportionate impact on those with little or no earned income, such as children, full-time mothers and seniors.
Conservative groups such as ...
continue reading...
